4.7 Article

Identifying infants at high risk of peanut allergy: The Learning Early About Peanut Allergy (LEAP) screening study

期刊

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
卷 131, 期 1, 页码 135-U215

出版社

MOSBY-ELSEVIER
DOI: 10.1016/j.jaci.2012.09.015

关键词

Peanut sensitization; peanut allergy; allergy risk factors; eczema; egg allergy; patient recruitment; allergy prevention; LEAP study

资金

  1. Immune Tolerance Network
  2. National Institute of Allergy and Infectious Diseases
  3. Food Allergy Initiative, New York, NY
  4. Food Standards Agency, United Kingdom
  5. Food Allergy and Anaphylaxis Network, Fairfax, Va
  6. MRC & Asthma UK Centre
  7. King's College London
  8. King's College Hospital NHS Foundation Trust
  9. National Peanut Board, Atlanta, Ga
  10. Immune Tolerance Network (ITN)
  11. National Institute of Allergy and Infectious Diseases (NIAID)
  12. National Institutes of Health
  13. ITN/NIAID
  14. Food Allergy Initiative
  15. National Peanut Board
  16. Food Standards Agency
  17. Food Allergy & Anaphylaxis Network
  18. Department of Health through the National Institute for Health Research Comprehensive Biomedical Research Centre award
  19. ITN
  20. Food Allergy and Anaphylaxis Network
  21. Sodilac
  22. Novartis
  23. Nestle Nutrition
  24. GlaxoSmithKline
  25. Serono Symposia International Foundation

向作者/读者索取更多资源

Background: Peanut allergy (PA) is rare in countries in which peanuts are introduced early into infants' diets. Learning Early About Peanut Allergy (LEAP) is an interventional study aiming to assess whether PA can be prevented by oral tolerance induction. Objective: We sought to characterize a population screened for the risk of PA. Methods: Subjects screened for the LEAP interventional trial comprise the LEAP screening study cohort. Infants were aged 4 to 10 months and passed a prescreening questionnaire. Results: This analysis includes 834 infants (mean age, 7.8 months). They were split into the following: group I, patients with mild eczema and no egg allergy (n = 118); group II, patients with severe eczema, egg allergy, or both but 0-mm peanut skin prick test (SPT) wheal responses (n = 542); group III, patients with severe eczema, egg allergy, or both and 1- to 4-mm peanut wheal responses (n = 98); and group IV, patients with greater than 4-mm peanut wheal responses (n = 76). Unexpectedly, many (17%) in group II had peanut-specific IgE sensitization (>= 0.35 kU/L); 56% of group III were similarly sensitized. In contrast, none of the patients in group I and 91% of those in group IV had peanut-specific IgE sensitization. Sensitization on skin testing to peanut (SPT response of 1- 4 mm vs 0 mm) was associated with egg allergy and severe eczema (odds ratio [OR], 2.31 [95% CI, 1.39-3.86] and 2.47 [95% CI, 1.14-5.34], respectively). Similar associations were observed with specific IgE sensitization. Black race was associated with a significantly higher risk of peanut-specific IgE sensitization (OR, 5.30 [95% CI, 2.85-9.86]). Paradoxically, for a given specific IgE level, black race was protective against cutaneous sensitization (OR, 0.15 [95% CI, 0.04-0.61]). Conclusion: Egg allergy, severe eczema, or both appear to be useful criteria for identifying high-risk infants with an intermediate level of peanut sensitization for entry into a PA prevention study. The relationship between specific IgE level and SPT sensitization needs to be considered within the context of race. (J Allergy Clin Immunol 2013;131:135-43.)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据